Melanoma Clinical Trials

Showing 261-280 of 1,292 trials

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT06398418

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

Solid Tumor, AdultSolid TumorMelanoma+3 more

Rise Therapeutics LLC33 participantsStarted Aug 2025

Nashville, Tennessee, United States

COMPLETEDPhase 1

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

NCT04772989

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)Melanoma+7 more

Arcus Biosciences, Inc.94 participantsStarted Mar 2021

Los Angeles, California, United States • Jacksonville, Florida, United States • Goshen, Indiana, United States +19 more locations

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Related Searches

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Tranexamic Acid in Nasal Mohs Reconstruction

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

HS-IT101 Injection in the Treatment of Advanced Melanoma

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node